ArticleScientific reports2026

Multitargeted comparative evaluation suggests 2-Aoeobenoxmide shows favourable in silico binding compared to Tucatinib against ERα, HER2, AKT1, EGFR, and PIK3CA in breast cancer.

Mohammed H Al-Qahtani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.